Transforming growth factor-β1 in autoimmune hepatitis: Correlation of liver tissue expression and serum levels with disease activity

Journal of Hepatology

Volumn 28, Issue 5, 1998, Pages 803-811

  Bayer, Elke M ^a   Herr, Wolfgang ^a   Kanzler, Stephan ^a   Waldmann, Christine ^a   Meyer Zum Büschenfelde, Karl Hermann ^a   Dienes, Hans P ^a   Lohse, Ansgar W ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Autoimmune hepatitis; ELISPOT; Fibrogenesis; Immunosuppression; In situ hybridization; Transforming growth factor 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROGENESIS; HISTOLOGY; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; MALE; MEDIATOR RELEASE; PRIORITY JOURNAL;

EID: 0032079771     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80230-4     Document Type: Article

References (30)

1. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission. N Engl J Med. 304:1981;5-9.
2. Thaler H. The natural history of chronic hepatitis. Schaffner F, Sherlock S, Leevy CM. The Liver and its Diseases. 1974;207-215 Stratton Intercontinental Medical Books, New York.
3. Bedossa P, Paradis V. Transforming growth factor-β (TGF-β): a key role in liver fibrogenesis. J Hepatol. 22:1995;37-42. (Suppl 2).
4. 1 with hepatic fibrosis. J Cell Biol. 108:1989;2477-2482.
5. 2 are differentially expressed in fibrotic liver disease. Am J Pathol. 139:1991;1221-1229.
6. Czaja AJ. Diagnosis, prognosis, and treatment of classical autoimmune chronic hepatitis. Krawitt EL, Wiesner RH. Autoimmune Liver Diseases. 1991;143-166 Raven Press, New York.
7. Johnson PJ, McFarlane IG, Eddleston ALWF. The natural course and heterogenity of autoimmune-type chronic active hepatitis. Semin Liver Dis. 11:1991;187-196.
8. Meyer zum Büschenfelde K-H, Lohse AW, Manns M, Poralla T. Autoimmunity and liver disease. Hepatology. 12:1990;354-363.
9. Lohse AW, Kögel M, Meyer zum Büschenfelde K-H. Evidence for spontaneous immunosuppression in autoimmune hepatitis. Hepatology. 22:1995;381-388.
10. Roberts AB, Sporn MB. Sporn MB, Roberts AB. The Handbook of Experimental Pharmacology. Peptide Growth Factors and their Receptors. 1989;419-472 Springer-Verlag, Heidelberg.
11. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors. 8:1993;1-9.
12. 1. J Immunol. 147:1991;1792-1796.
13. 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA. 88:1991;2918-2921.
14. 1. J Immunol. 146:1991;3012-3017.
15. 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest. 87:1991;1108-1113.
16. Johnson PJ, McFarlane IG. Meeting Report: International Autoimmune Hepatitis Group. Hepatology. 18:1993;998-1095.
17. Kanzler S, Gerken G, Dienes HP, Meyer zum Büschenfelde K-H, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy. Z Gastroenterol. 35:1997;571-578.
18. 2) secreted by cells in culture. J Cell Physiol. 138:1989;79.
19. Bissell MD, Wang S-S, Jarnagin WR, Roll FJ. Cell specific expression of transforming growth factor-beta in rat liver. J Clin Invest. 447-455:1995.
20. 1 receptors in normal, cirrhotic and neoplastic human livers. Hepatology. 21:1995;760-766.
21. 1) in chronic hepatitis C [abstract]. Hepatology. 22:1995;336.
22. 1, and a different tissue distribution. J Clin Invest. 86:1990;1976-1984.
23. Jakowlew SB, Mead JE, Danielpour D, Wu J, Roberts AB, Fausto N. Transforming growth factor-β (TGF-β) isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-β Cell Regul. 2:1991;535-548.
24. Rosenbaum J, Blazejewski S. Regulation of Ito cell proliferation by soluble factors. J Hepatol. 22:1995;65-70. (Suppl. 21).
25. Friedman SL. The cellular basis of hepatic fibrosis. N Engl J Med. 328:1993;1828-1835.
26. 1 and α in chronic liver disease. N Engl J Med. 324:1991;933-936.
27. 1 gene expression in human liver disease. J Hepatol. 14:1992;259-264.
28. Weiner FR, Giabrone M-A, Czaja MJ, Shah A, Annoni G, Takahashi S, et al. Ito-cell gene expression and collagen regulation. Hepatology. 11:1990;111-117.
29. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor-beta, interleukin 4 and prostaglandin E expression in the brain. J Exp Med. 176:1992;1355-1364.
30. Czaja AJ, Herschel A, Carpenter PJ, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology. 104:1993;1755-1761.